At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions, such as haemophilia, growth disorders, and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries.

Novo Nordisk is project leader of the Hypo-RESOLVE consortium and industry co-lead for several work packages.

Dr Stephen Gough

MD FRCP (UK), Senior Vice President, Global Chief Medical Officer, joined Novo Nordisk A/S, as Senior Principal Clinical Scientist in Copenhagen, Denmark in 2015 in the Chief Medical Office, to provide advice and clinical guidance on the development of new molecules and drugs, from early through to phase III and beyond, for the treatment of diabetes and obesity. In 2018, Stephen became Senior Vice President and Global Chief Medical Officer.

Prior to joining Novo Nordisk, Stephen was Head of the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), in the UK and served as Professor of Diabetes to the University of Oxford and Consultant Physician at the Oxford University of Hospitals NHS Trust. He was also the Diabetes Clinical Lead for the Local Clinical Research Network and the Academic Health Science Network in Oxford.

His research interests have resided in the fields of the genetics of autoimmune disease, glucose homeostasis, incretin biology in pancreas whole organ and islet transplantation, and clinical trials of GLP-1 based therapies. Since joining Novo Nordisk he has supported a number of activities and provided senior medical opinion in diabetes, obesity and biopharm.

Dr Matthias Müllenborn

Director, R&D, Alliances and Innovation Outreach, works as an alliance manager with external innovation and public-private partnerships.

Matthias holds a Master’s Degree in Physics from the Westfälische Wilhelms-Universität Münster, Germany and a PhD from UCLA, California, USA. He worked as an Associate Professor at Nanotech at the Technical University of Denmark, and as CEO for Sonion’s MEMS microphone spin-off. From 2003 to 2017, he was with Oticon leading product development within new technology, bone anchored hearing instruments, and cochlear implants. Matthias Müllenborn has a long experience with managing complex projects involving many internal and external stakeholders, including EU funded projects.

Dr Erica Nishimura

Scientific Vice President, Diabetes Research, obtained a PhD in Physiology from the University of British Columbia, Canada, in the field of gastro-intestinal hormones and was a post-doctoral research fellow in the Peptide Biology Laboratory at the Salk Institute, La Jolla California, where she studied neuroendocrine hormone receptors.

Erica joined NN in 1991 as a principle investigator at the Hagedorn Research Institute where she studied the role of glucagon in the pathophysiology of type 2 diabetes and the possible therapeutic benefits of glucagon receptor antagonists. Since 2000, Erica has focussed on the biological characterization of novel insulin analogues and has specialized in the development of new insulin therapies. In her current role as Scientific VP in Global Research, she is overseeing the later stage insulin research projects.

Dr Mari-Anne Gall

International Medical Vice President, M&S Insulin & Devices, qualified in medicine from the University of Copenhagen, Denmark. She trained in clinical diabetes at the Hvidøre Hospital, Klampenborg and undertook a research fellowship at the Hvidøre Hospital and the Steno Diabetes Center, Gentofte, until she joined NN in 1993. She became Doctor of Medical Science (DMSc) from the University of Copenhagen in 1997 (thesis entitled: Albuminuria in Non-Insulin-Dependent Diabetes Mellitus: Prevalence, Causes, and Consequences.).

Her current position as International Medical Vice President (IMVP), Medical & Science Insulin & Devices, Global Development, NN since July 2014. Previously, she held positions including: IMVP in various insulin analogue development projects, International Clinical Project Manager and Senior Principal Scientist for clinical development of oral anti-diabetic agents and pulmonary insulin. In her past and current positions, she has been involved in the planning and preparation of clinical development programmes, submissions and clinical trials.

Dr Jens Heisterberg

VP Regulatory Affairs Intelligence, is currently heading up Regulatory Intelligence at NN. Until May 2016, he was Chief Medical Officer at the Licensing Division of the Danish Medicines Agency, a position he had held since February 2010. He was also member of the CHMP during that time. From 2002 to 2011 and again from 2013 to 2016, he worked part-time at the University of Copenhagen as external lecturer teaching clinical development methodology and clinical pharmacology. Prior to his affiliation with the Danish Medicines Agency, he worked with clinical drug development in the pharmaceutical industry for a combined period of over 10 years. He qualified as medical doctor from the University of Copenhagen in 1990 and as a clinical pharmacologist in 2002.

Sherina Kuruvilla

Associated Project Director, Global Patient Relations, Corporate Affairs – Sherina is currently responsible for leading the Research and Development (R&D) patient engagement and advocacy strategy for Novo Nordisk. She also represents Novo Nordisk externally in various forum focusing on patient engagement in R&D such as Innovative Medicines Initiative (IMI) and TransCelerate. Sherina joined Novo Nordisk in 2002 and has held various positions in the area of global clinical trial management and global medical affairs. She has over 15 years of clinical trial experience, while always having a strong focus on patient engagement and incorporating the patient voice in drug development. In her previous role, Sherina was responsible for the development of patient recruitment, education and retention strategies for several global phase 3 clinical programmes within the area of Diabetes and Obesity.